Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Enterprise Value (2021 - 2026)

bioAffinity Technologies has reported Enterprise Value over the past 6 years, most recently at -$3.1 million for Q1 2026.

  • Quarterly Enterprise Value fell 675.0% to -$3.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.1 million through Mar 2026, down 675.0% year-over-year, with the annual reading at -$6.4 million for FY2025, 483.54% down from the prior year.
  • Enterprise Value was -$3.1 million for Q1 2026 at bioAffinity Technologies, up from -$6.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$400000.0 in Q1 2025 and troughed at -$13.5 million in Q3 2022.
  • The 5-year median for Enterprise Value is -$3.1 million (2026), against an average of -$4.9 million.
  • Year-over-year, Enterprise Value skyrocketed 90.36% in 2024 and then plummeted 858.65% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$11.4 million in 2022, then skyrocketed by 75.28% to -$2.8 million in 2023, then skyrocketed by 60.83% to -$1.1 million in 2024, then crashed by 483.54% to -$6.4 million in 2025, then soared by 51.94% to -$3.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Enterprise Value are -$3.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$7.7 million (Q3 2025).